Rexulti 1 MG tablet 30S
Ended Awarded Last action
- Contract number
- SPE2DR26F4GL6
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $17,669
Award facts
- Contract value 100% obligated
- $17,669.44 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $17,669.44 to AmerSourceBergen Drug Corp for the supply of REXULTI (brexpiprazole) 1 mg tablets in a quantity of 30 on January 20, 2026, with completion expected by January 21, 2026. This competitive award with firm fixed pricing will be performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerSourceBergen Drug Corp's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop Support Medical, a comprehensive pharmaceutical prime vendor agreement valued at up to $999,999,999.00 and extending through December 2031, which authorizes the supply of brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities to support military healthcare programs globally.
REXULTI is an atypical antipsychotic medication primarily used in the treatment of major depressive disorder and schizophrenia. As a subsidiary of Cencora, Inc., AmerSourceBergen Drug Corp operates as a critical pharmaceutical distributor for federal medical procurement, serving the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The non-set-aside status of this award reflects the contractor's demonstrated capability to compete and perform under full and open competition, consistent with its established track record fulfilling federal medical supply requirements across multiple therapeutic domains.
Quick answers
Who was awarded contract SPE2DR26F4GL6?
SPE2DR26F4GL6 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 20, 2026.
How much is contract SPE2DR26F4GL6 worth?
The government has obligated $17,669 on SPE2DR26F4GL6.
Is contract SPE2DR26F4GL6 an order under another contract?
Yes. SPE2DR26F4GL6 is a delivery order under SPE2DR25D3015, an indefinite delivery contract.
Was contract SPE2DR26F4GL6 competed?
The extent of competition for SPE2DR26F4GL6 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award